Nanoscope Therapeutics Taps McKesson's InspiroGene for U.S. Rollout of Retinal Therapy
Event summary
- Nanoscope Therapeutics has selected InspiroGene by McKesson to handle U.S. commercialization services for its lead product, MOGENRY™, pending FDA approval.
- InspiroGene will manage specialty pharmacy, distribution, and patient hub services for the anticipated retinal therapy launch.
- Nanoscope's MCO platform is designed as a one-time, in-office treatment for retinal degenerative diseases, including retinitis pigmentosa and Stargardt disease.
- The company has initiated a rolling BLA submission to the FDA following positive Phase 2b/3 trial results for retinitis pigmentosa.
The big picture
Nanoscope's partnership with InspiroGene by McKesson underscores the strategic importance of robust commercialization infrastructure for advanced therapies. The deal highlights the growing trend of biotech companies leveraging specialized distribution networks to navigate the complexities of bringing gene therapies to market. With a rolling BLA submission underway and promising clinical data, Nanoscope is positioning itself to address a significant unmet need in retinal degenerative diseases, potentially capturing a substantial share of the $10B+ global retinal therapies market.
What we're watching
- Regulatory Approval
- The pace at which the FDA reviews Nanoscope's rolling BLA submission will determine the timeline for MOGENRY's commercial launch.
- Market Penetration
- Whether Nanoscope can establish MOGENRY as the standard of care for retinitis pigmentosa and other retinal diseases.
- Operational Execution
- How effectively InspiroGene by McKesson integrates Nanoscope's therapy into the U.S. healthcare system and supply chain.
Related topics